Nova Minerals (ASX:NVA) Soars on $43M US Critical Minerals Boost – Gold-Antimony Play to Watch
14 October 2025
2 mins read

Nova Minerals (ASX:NVA) Soars on $43M US Critical Minerals Boost – Gold-Antimony Play to Watch

  • Company: Nova Minerals (ASX:NVA; Nasdaq:NVA) is a dual-listed exploration/development company focused on gold and critical minerals. Its flagship Estelle Project (Alaska, 514 km²) hosts a JORC 9.9 million oz gold resource and large antimony (stibnite) deposits novaminerals.com.au globenewswire.com. Nova’s strategy is to advance Estelle toward production and develop a vertically‐integrated US antimony supply chain.
  • Recent News: In early Oct 2025 Nova announced key developments: a US$43.4 M grant from the US Department of War for antimony processing at Estelle globenewswire.com, plus a land-use permit for a planned refinery at Port MacKenzie globenewswire.com. On Oct 14 it was invited to brief US/Australian leaders ahead of the Oct 20 summit, triggering a stock rally globenewswire.com 1 .
  • Stock Performance: NVA shares have jumped sharply. On 13 Oct the ASX share price closed ~$0.775, then ~0.90 on 14 Oct (a 7% daily gain) intelligentinvestor.com.au. In US markets the ADR nearly doubled pre-open on Oct 14 ca.investing.com. Year-to-date the stock is up ~147%, and up ~389% over 12 months stocktwits.com. (TradingView notes NVA has risen ~182% over the past month and ~400% year-over-year 2 .)
  • Fundamentals & Technicals: Nova remains pre-revenue with ongoing exploration spending – recent half-year net loss ~A$9M tradingview.com and market cap ~$300–310 M tradingview.com. Technically, most indicators are bullish: all moving averages (5,50,100,200-day) signal “Buy” and MACD is positive investing.com. Investing.com labels NVA a “Strong Buy” based on these signals, though the 14-day RSI (~79) is in overbought territory investing.com 3 .
  • Analysis & Commentary: Analysts note that Nova is now the first ASX-listed company to benefit from the US critical‑minerals push smallcaps.com.au. SmallCaps and media point out this US backing could re-rate ASX juniors with US projects smallcaps.com.au oilprice.com. Nova’s CEO Gerteisen emphasizes that antimony is now a US strategic mineral, and Nova “is well-positioned to contribute to both U.S. and Australian critical minerals strategies” oilprice.com. However, expert commentary (e.g. Simply Wall St) cautions that expectations are high: execution risk and further funding needs mean the stock could be “on the expensive side” after this run-up simplywall.st 4 .
  • Outlook: In the short term, NVA may remain volatile. The Oct 20 Trump–Albanese summit and subsequent announcements could trigger further moves. In the long run, success hinges on executing Estelle’s development: if Nova can bring production online (targeting 2026/27 for military-grade antimony) it could validate bullish forecasts. (For context, a 2024 analyst report gave a US$25 ADR target novaminerals.com.au, and mid-2023 targets implied A$1–$2+ by 2025–26 novaminerals.com.au – vastly above current prices.) However, those high targets assume major advances and stable funding. Investors should weigh the large resource base and government support against the usual exploration risks (timeline delays, cost overruns, further dilution).

Sources: Nova Minerals official releases and filings novaminerals.com.au globenewswire.com; market news (Investing.com, OilPrice, Stocktwits, SmallCaps, SimplyWallSt) ca.investing.com oilprice.com stocktwits.com smallcaps.com.au simplywall.st; ASX trading data intelligentinvestor.com.au; technical data (Investing.com) investing.com investing.com; analyst reports novaminerals.com.au novaminerals.com.au. Each cited source provides background and verification for the above analysis.

A technology and finance expert writing for TS2.tech. He analyzes developments in satellites, telecommunications, and artificial intelligence, with a focus on their impact on global markets. Author of industry reports and market commentary, often cited in tech and business media. Passionate about innovation and the digital economy.

Stock Market Today

AstraZeneca stock price: What could move AZN next week as earnings loom

AstraZeneca stock price: What could move AZN next week as earnings loom

7 February 2026
AstraZeneca shares rose Friday, closing at $193.03 in New York, up 3.1%, and 14,104p in London, up 0.9%. The company reports full-year and Q4 2025 results Tuesday, with investors focused on 2026 guidance. The FDA this week issued a complete response letter for a subcutaneous Saphnelo filing, while granting Priority Review to Datroway for breast cancer. AstraZeneca recently shifted its primary U.S. listing to the NYSE.
Toyota stock price rises on CEO shake-up and higher profit outlook as buyout deadline nears

Toyota stock price rises on CEO shake-up and higher profit outlook as buyout deadline nears

7 February 2026
Toyota shares rose 2% to 3,780 yen Friday after the company raised its full-year profit forecast and announced CFO Kenta Kon will replace CEO Koji Sato on April 1. Third-quarter net revenues climbed 6.8% to 38.087 trillion yen, but North America posted a 5.6 billion yen operating loss. Toyota’s U.S. ADRs closed up 2.9%. The tender offer for Toyota Industries shares closes Feb. 12.
Cyngn (CYN) Stock Soars 500% on Nvidia Tie-Up – Bull Run or Bubble? Latest News, Forecasts & Risks
Previous Story

Cyngn (CYN) Stock Soars 500% on Nvidia Tie-Up – Bull Run or Bubble? Latest News, Forecasts & Risks

Strata Skin Sciences (SSKN) Stock Surges on Laser-Therapy Breakthrough – Buy, Hold or Sell?
Next Story

Strata Skin Sciences (SSKN) Stock Surges on Laser-Therapy Breakthrough – Buy, Hold or Sell?

Go toTop